1. Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
- Author
-
Pichler, Renate, Fritz, Josef, Mari, Andrea, Cadenar, Anna, Deimling, Markus von, Marcq, Gautier, Giudice, Francesco del, Leonardo, Costantino, Bologna, Eugenio, Mori, Keiichiro, Tahbaz, Rana, Santis, Maria De, Klatte, Tobias, Erber, Barbara, Lackner, Felizian, Kronbichler, Andreas, Seeber, Andreas, Fisch, Margit, Moschini, Marco, and Pradere, Benjamin
- Subjects
KIDNEY physiology ,BLADDER tumors ,CYSTECTOMY ,PEARSON correlation (Statistics) ,CISPLATIN ,CREATININE ,LOGISTIC regression analysis ,RETROSPECTIVE studies ,CANCER patients ,DESCRIPTIVE statistics ,ELIGIBILITY (Social aspects) ,COMBINED modality therapy ,RESEARCH ,STATISTICS ,DATA analysis software ,GLOMERULAR filtration rate - Abstract
Background To examine the agreement of different calculated estimated glomerular filtration rate (eGFR) formulas and measured creatinine clearance (CrCI) at the primary diagnosis of muscle-invasive bladder cancer (MIBC). Materials and Methods We performed a multicenter analysis of patients with MIBC, treated with cisplatin-based neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), or with RC alone, between 2011 and 2021. Baseline eGFR was computed using 4 calculated serum equations including Cockcroft-Gault (CG), MDRD, CKD-EPI 2009, and race-free CKD-EPI 2021. To examine the association between calculated eGFR and measured CrCI, subgroup analyses were performed among patients in whom measured 24-hour urine CrCl was determined. Cisplatin-ineligibility was defined as CrCI and/or eGFR < 60 mL/minute per 1.73 m
2 . Results Of 956 patients, 30.0%, 33.3%, 31.9%, and 27.7% were found to be cisplatin-ineligible by the CG, MDRD, CKD-EPI, and race-free CKD-EPI equations (P = .052). The concordance between calculated eGFR formulas was rated substantial (Cohen's kappa (k): 0.66-0.95). Among the subgroup (n = 245) with measured CrCl, 37 (15.1%) patients had a CrCI less than 60 mL/minute. Concordance between measured CrCl and calculated eGFR was poor (ĸ : 0.29-0.40). All calculated eGFR formulas markedly underestimated the measured CrCI. Specifically, 78%-87.5% of patients with a calculated eGFR between 40 and 59 mL/minute exhibited a measured CrCI ≥ 60 mL/minute. Conclusions Comparing calculated eGFR formulas, similar percentages of patients with MIBC were deemed cisplatin-ineligible. However, a significant number of patients could be upgraded by being cisplatin-fit based on measured CrCI, particularly when the calculated eGFR was falling within the gray range of 40-59 mL/minute. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF